Clinical Trials Directory

Trials / Unknown

UnknownNCT04170582

Patient Registry for Patients With Chronic Subdural Hematoma

Status
Unknown
Phase
Study type
Observational
Enrollment
250 (estimated)
Sponsor
Heinrich-Heine University, Duesseldorf · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

All admitted patients diagnosed with unilateral or bilateral chronic subdural hematoma are included into this registry after consent. Clinical condition, radiological details, therapy (intervention/medication treatment/conservative) and outcome are documented. Patient follow-up is documented over at least 24 month with focus on neurological condition (NIHSS), cognitive impairment (MoCA) and quality of life (SF-12 ver. 2).

Detailed description

Chronic subdural hematoma (cSDH) is a frequent disease in- predominantly - elderly patients often caused by minor trauma to the bridging veins eventually leading to a collection of old blood in the subdural space over time. Besides age of the patients a number of further risk factors are assumed to favor pathogenesis. Depending on size and location of blood collections diverse neurological symptoms can be seen. Therapy approaches are heterogeneous ranging from conservative treatment with or without medication to surgical treatment. There also is lacking knowledge regarding neurocognitive impairment and effects on quality of life in patients under different therapy regimes. The prospective patient registry will enclose all patients admitted to the investigator's department diagnosed with cSDH either by MRI or CT scan after informed consent. Medical history, regular medication, social status, radiological findings and neurological examination using NIHSS will be performed at time of inclusion, discharge and follow-up. Additionally, neurocognitive testing and documentation of Quality of Life using MOCA Test and SF-12 will be conducted at different timepoints. Moreover a detailed documentation of therapy strategies is implemented in the study protocol. With this registry the study group expects to obtain significant data leading to a more standardized and optimized therapy regime and furthermore widening understanding on so far rarely known impact of cSDH on neurocognition and quality of life.

Conditions

Timeline

Start date
2020-01-01
Primary completion
2024-12-01
Completion
2025-01-01
First posted
2019-11-20
Last updated
2023-03-02

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT04170582. Inclusion in this directory is not an endorsement.